Abstract
Determined efficacies of benzoyl peroxide may be affected by study design, implementation, and vehicle effects. We sought to elucidate areas that may allow improvement in determining accurate treatment efficacies by determining rates of active treatment and vehicle responders in randomized controlled trials assessing the efficacy of topical benzoyl peroxide to treat acne. We conducted a systematic review of randomized vehicle-controlled trials evaluating the efficacy of topical benzoyl peroxide for the treatment of acne. We compared response rates of vehicle treatment arms versus those in benzoyl peroxide arms. Twelve trials met inclusion criteria with 2818 patients receiving benzoyl peroxide monotherapy treatment and 2004 receiving vehicle treatment. The average percent reduction in total number of acne lesions was 44.3 (SD = 9.2) and 27.8 (SD = 21.0) for the active and vehicle treatment groups, respectively. The average reduction in non-inflammatory lesions was 41.5 % (SD = 9.4) in the active treatment group and 27.0 % (SD = 20.9) in the vehicle group. The average percent decrease in inflammatory lesions was 52.1 (SD = 10.4) in the benzoyl peroxide group and 34.7 (SD = 22.7) in the vehicle group. The average percentage of participants achieving success per designated study outcomes was 28.6 (SD = 17.3) and 15.2 (SD = 9.5) in the active treatment and vehicle groups, respectively. Patient responses in randomized controlled trials evaluating topical acne therapies may be affected by clinical trial design, implementation, the biologic effects of vehicles, and natural disease progression. “No treatment” groups may facilitate determination of accurate treatment efficacies.
Similar content being viewed by others
References
Albuquerque RG, Rocha MA, Bagatin E, Tufik S, Andersen ML (2014) Could adult female acne be associated with modern life? Arch Dermatol Res 306:683–688
Beecher HK (1955) The powerful placebo. J Am Med Assoc 159:1602–1606
Benedetti F, Carlino E, Pollo A (2011) Hidden administration of drugs. Clin Pharmacol Ther 90:651–661
Bergfeld WF (2004) The pathophysiology of acne vulgaris in children and adolescents, part 2: tailoring treatment. Cutis 74:189–192
Borovaya A, Dombrowski Y, Zwicker S, Olisova O, Ruzicka T, Wolf R, Schauber J, Sardy M (2014) Isotretinoin therapy changes the expression of antimicrobial peptides in acne vulgaris. Arch Dermatol Res 306:689–700
Burkhart CG (2006) A chemical look at benzoyl peroxide may prove helpful. J Drugs Dermatol 5:705
Chalker DK, Shalita A, Smith JG Jr, Swann RW (1983) A double-blind study of the effectiveness of a 3 % erythromycin and 5 % benzoyl peroxide combination in the treatment of acne vulgaris. J Am Acad Dermatol 9:933–936
Chiou WL (2012) Low intrinsic drug activity and dominant vehicle (placebo) effect in the topical treatment of acne vulgaris. Int J Clin Pharmacol Ther 50:434–437
Colloca L, Miller FG (2011) How placebo responses are formed: a learning perspective. Philos Trans R Soc Lond B Biol Sci 366:1859–1869
Del Rosso JQ, Tanghetti E (2006) The clinical impact of vehicle technology using a patented formulation of benzoyl peroxide 5 %/clindamycin 1 % gel: comparative assessments of skin tolerability and evaluation of combination use with a topical retinoid. J Drugs Dermatol 5:160–164
Draelos ZD, Callender V, Young C, Dhawan SS (2008) The effect of vehicle formulation on acne medication tolerability. Cutis 82:281–284
Eady EA (1998) Bacterial resistance in acne. Dermatol 196:59–66
Eady EA, Farmery MR, Ross JI, Cove JH, Cunliffe WJ (1994) Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and resistant skin bacteria from acne patients. Br J Dermatol 131:331–336
Eady EA, Gloor M, Leyden JJ (2003) Propionibacterium acnes resistance: a worldwide problem. Dermatol 206:54–56
Ede M (1973) A double-blind, comparative study of benzoyl peroxide, benzoyl peroxide–chlorhydroxyquinoline, benzoyl peroxide–chlorhydroxyquinoline–hydrocortisone, and placebo lotions in acne. Curr Ther Res Clin Exp 15:624–629
Eichenfield LF, Alio Saenz AB (2011) Safety and efficacy of clindamycin phosphate 1.2 %-benzoyl peroxide 3 % fixed-dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double-blind, active- and vehicle-controlled study. J Drugs Dermatol 10:1382–1396
Embil K, Nacht S (1996) The Microsponge Delivery System (MDS): a topical delivery system with reduced irritancy incorporating multiple triggering mechanisms for the release of actives. J Microencapsul 13:575–588
Fakhouri T, Yentzer BA, Feldman SR (2009) Advancement in benzoyl peroxide-based acne treatment: methods to increase both efficacy and tolerability. J Drugs Dermatol 657–661
Feldman SR, Fleischer AB Jr (2007) A method to gain a sense of relative efficacy of acne medications that have not yet been studied. J Drugs Dermatol 6:976
Feldman SR, Tan J, Poulin Y, Dirschka T, Kerrouche N, Manna V (2011) The efficacy of adapalene–benzoyl peroxide combination increases with number of acne lesions. J Amer Acad Dermatol 64:1085–1091
Fluhr JW, Barsom O, Gehring W, Gloor M (1999) Antibacterial efficacy of benzoyl peroxide in phospholipid liposomes. A vehicle-controlled, comparative study in patients with papulopustular acne. Dermatol 198:273–277
Ghali F, Kang S, Leyden J, Shalita AR, Thiboutot DM (2009) Changing the face of acne therapy. Cutis 83:4–15
Gold LS, Tan J, Cruz-Santana A, Papp K, Poulin Y, Schlessinger J, Gidner J, Liu Y, Graeber M (2009) A North American study of adapalene–benzoyl peroxide combination gel in the treatment of acne. Cutis 84:110–116
Gollnick HP, Draelos Z, Glenn MJ, Rosoph LA, Kaszuba A, Cornelison R, Gore B, Liu Y, Graeber M (2009) Adapalene–benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 161:1180–1189
Hughes BR, Norris JF, Cunliffe WJ (1992) A double-blind evaluation of topical isotretinoin 0.05 %, benzoyl peroxide gel 5 % and placebo in patients with acne. Clin Exp Dermatol 17:165–168
Ito S (2011) Placebo in clinical trials. Clin Pharmacol Ther 90:637–639
Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, Kirsch I, Schyner RN, Nam BH, Nguyen LT, Park M, Rivers AL, McManus C, Kokkotou E, Drossman DA, Goldman P, Lembo AJ (2008) Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. Br Med J 336:999–1003
Kircik L, Friedman A (2010) Optimizing acne therapy with unique vehicles. J Drugs Dermatol 9:s53–s57
Kligman AM (1995) Acne vulgaris: tricks and treatments. Part II: the benzoyl peroxide saga. Cutis 56:260–261
Klinger R, Soost S, Flor H, Worm M (2007) Classical conditioning and expectancy in placebo hypoalgesia: a randomized controlled study in patients with atopic dermatitis and persons with healthy skin. Pain 128:31–39
Leyden JJ, Berger RS, Dunlap FE, Ellis CN, Connolly MA, Levy SF (2001) Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. Am J Clin Dermatol 2:33–39
Linde K, Witt CM, Streng A, Weidenhammer W, Wagenpfeil S, Brinkhaus B, Willich SN, Melchart D (2007) The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain 128:264–271
Lookingbill DP, Chalker DK, Lindholm JS, Katz HI, Kempers SE, Huerter CJ, Swinehart JM, Schelling DJ, Klauda HC (1997) Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 37:590–595
Lucchina LC, Kollias N, Gillies R, Phillips SB, Muccini JA, Stiller MJ, Trancik RJ, Drake LA (1996) Fluorescence photography in the evaluation of acne. J Am Acad Dermatol 35:58–63
Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY (1999) The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 140:672–676
Mills OH Jr, Kligman AM, Pochi P, Comite H (1986) Comparing 2.5 %, 5 %, and 10 % benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol 25:664–667
Nino M, Calabro G, Santoianni P (2010) Topical delivery of active principles: the field of dermatological research. Dermatol Online J 16:4
No authors listed (2009) Benzoyl peroxide microsphere formulations: what is the science supporting microsphere vehicle technology and clinical use? J Clin Aesthet Dermatol. 2(9):46–54
Ozolins M, Eady EA, Avery AJ, Cunliffe WJ, Po AL, O’Neill C, Simpson NB, Walters CE, Carnegie E, Lewis JB, Dada J, Haynes M, Williams K, Williams HC (2004) Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet 364:2188–2195
Pawin H, Beylot C, Chivot M, Faure M, Poli F, Revuz J, Dreno B (2004) Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol 14:4–12
Pochi PE, Shalita AR, Strauss JS, Webster SB, Cunliffe WJ, Katz HI, Kligman AM, Leyden JJ, Lookingbill DP, Plewig G (1991) Report of the Consensus Conference on Acne Classification. Washington, D.C., March 24 and 25, 1990. J Am Acad Dermatol 24:495–500
Sanclemente G, Acosta JL, Tamayo ME, Bonfill X, Alonso-Coello P (2014) Clinical practice guidelines for treatment of acne vulgaris: a critical appraisal using the AGREE II instrument. Arch Dermatol Res 306:269–277
Stewart-Williams S, Podd J (2004) The placebo effect: dissolving the expectancy versus conditioning debate. Psycholog Bull 130:324–340
Stone DA, Kerr CE, Jacobson E, Conboy LA, Kaptchuk TJ (2005) Patient expectations in placebo-controlled randomized clinical trials. J Eval Clin Prac 11:77–84
Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, Liu Y, Graeber M, Kang S (2007) Adapalene–benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 57:791–799
Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D (2008) An aqueous gel fixed combination of clindamycin phosphate 1.2 % and benzoyl peroxide 2.5 % for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 59:792–800
Tschen EH, Katz HI, Jones TM, Monroe EW, Kraus SJ, Connolly MA, Levy SF (2001) A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis 67:165–169
Wester RC, Patel R, Nacht S, Leyden J, Melendres J, Maibach H (1991) Controlled release of benzoyl peroxide from a porous microsphere polymeric system can reduce topical irritancy. J Am Acad Dermatol 24:720–726
White GM (1998) Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol 39:S34–S37
Younis S, Javed Q (2014) The interleukin-6 and interleukin-1A gene promoter polymorphism is associated with the pathogenesis of acne vulgaris. Arch Dermatol Res. doi:10.1007/s00403-014-1519-x:
Acknowledgments
We thank Gloria Won of Fishbon library for her assistance with database searching.
Conflict of interest
The authors declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lamel, S.A., Sivamani, R.K., Rahvar, M. et al. Evaluating clinical trial design: systematic review of randomized vehicle-controlled trials for determining efficacy of benzoyl peroxide topical therapy for acne. Arch Dermatol Res 307, 757–766 (2015). https://doi.org/10.1007/s00403-015-1568-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-015-1568-9